mecprolabs
New member
Excerpts from article about GW501516
Anti-doping agency warns cheats on the health risks of Endurobol
The recent WADA warning was therefore not prompted by recent findings of adverse human health effects per se, but rather the concern of the substance’s ready availability and abuse by athletes.
It is understood that a Russian cyclist (European track champion Valery Kaikov) has yesterday been named as the first athlete to be tested positive for the drug.
Human studies on the effects of GW501516 include the following:
•Phase I trial: multicentre trial conducted between 2004-12.
•Phase II trial: trial approved in Belgium and conducted between 2004-11. Results not published.
•Phase IV trials: conducted in Australia between 2003-08.
•Non-GSK-affiliatied anti-doping research: conducted between 2009-12.
•High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor.
•Research into Peroxisome Proliferator–Activated Receptor effects in obese men.
There were no side-effects reported in the human studies.
But this may be due to short study durations. It may also be due to the small doses used in humans.
The side-effects of GW501516 from animal studies were based on large doses of the drug.
There are at present at least eight separate clinical trials being conducted using other drugs of the PPAR class and they are in various stages of development.
Buy GW501516 - MecProLabs
Anti-doping agency warns cheats on the health risks of Endurobol
The recent WADA warning was therefore not prompted by recent findings of adverse human health effects per se, but rather the concern of the substance’s ready availability and abuse by athletes.
It is understood that a Russian cyclist (European track champion Valery Kaikov) has yesterday been named as the first athlete to be tested positive for the drug.
Human studies on the effects of GW501516 include the following:
•Phase I trial: multicentre trial conducted between 2004-12.
•Phase II trial: trial approved in Belgium and conducted between 2004-11. Results not published.
•Phase IV trials: conducted in Australia between 2003-08.
•Non-GSK-affiliatied anti-doping research: conducted between 2009-12.
•High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor.
•Research into Peroxisome Proliferator–Activated Receptor effects in obese men.
There were no side-effects reported in the human studies.
But this may be due to short study durations. It may also be due to the small doses used in humans.
The side-effects of GW501516 from animal studies were based on large doses of the drug.
There are at present at least eight separate clinical trials being conducted using other drugs of the PPAR class and they are in various stages of development.
Buy GW501516 - MecProLabs
